Patents Examined by Shawquia Jackson
  • Patent number: 12378254
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: August 5, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Patent number: 12377067
    Abstract: The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and/or frequency of ralinepag and/or riociguat, reduced doses and/or frequency of ralinepag and/or treprostinil, and reduced doses and/or frequency of ralinepag and/or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and/or iloprost monotherapies.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 5, 2025
    Assignees: ARENA PHARMACEUTICALS, INC.
    Inventors: Dominic P. Behan, John W. Adams, Lucie H. Clapp
  • Patent number: 12369583
    Abstract: The present invention relates to the use of N-methoxy(phenylethyl)-pyrazole carboxamides for the control of nematodes in agriculture and as antihelminthic agents against endoparasites in animals and humans, as well as compositions comprising such compounds. The present invention 5 further relates to the use of these compounds or compositions for controlling nematodes and/or helminths, in particular for controlling plant parasitic nematodes, and to the use of these compounds in preparing nematicidal and/or antihelminthic compositions.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: July 29, 2025
    Assignee: SYNGENTA CROP PROTECTION AG
    Inventors: Domenica Jenni, Brigitte Slaats, Ana Cristina Dutton
  • Patent number: 12371405
    Abstract: The present invention relates to an isoindol-sulfilimine compound and its preparation and its use as a sigma-2 receptor inhibitor. Compared with the prior art, the isoindol-sulfilimine compound prepared by the present invention can effectively inhibit the sigma-2 receptor activity by binding to the sigma-2 receptor and deformationally regulating the sigma-2 receptor complex, which will lead to the instability of the binding of adjacent A? oligomers to the receptor on the synapse, thus leading to the removal of AB oligomers from the synapse. It can be further used for the preparation of new therapeutic drugs for tumor and neurodegenerative diseases.
    Type: Grant
    Filed: February 20, 2025
    Date of Patent: July 29, 2025
    Assignee: SHANGHAI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES
    Inventors: Xiuhong Lu, Gang Huang, Anyang Sun, Yongsheng Zhang, Jincheng Wang, Jinjing He
  • Patent number: 12365801
    Abstract: Disclosed herein, inter alia, are silicon containing detectable compounds and methods of use thereof. In an aspect is provided a monovalent nucleotide or monovalent nucleoside covalently bound to a monovalent form of a compound described herein (e.g., wherein the R13 moiety of a compound described herein has reacted with a bioconjugate reactive group to form a bioconjugate linker thereby covalently bonding the monovalent compound to the monovalent nucleotide or monovalent nucleoside).
    Type: Grant
    Filed: March 29, 2024
    Date of Patent: July 22, 2025
    Assignee: Singular Genomics Systems, Inc.
    Inventors: Megha Cila, Ronald Graham, Rodrigo Rodriguez
  • Patent number: 12364696
    Abstract: The present invention relates to methods and compositions for the treatment of autoimmune diseases and of excessive hair shedding or hair loss in a subject or for promoting hair growth in a subject wherein the subject has an autoimmune hair loss disorder, such as alopecia areata. The methods and compositions comprise the administration of a janus kinase inhibitor, such as tofacitinib, wherein the inhibitor is predominantly absorbed through the oral mucosal routes such as the sublingual mucosa.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 22, 2025
    Assignee: JAK Slave Pty Ltd
    Inventors: Rodney Sinclair, Yuk-Shui Andrew Lau
  • Patent number: 12357632
    Abstract: Provided herein are methods of treating advanced or metastatic cholangiocarcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof, wherein the patient has progression of the cholangiocarcinoma after previous administration of another therapy.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: July 15, 2025
    Assignee: QED Therapeutics, Inc.
    Inventors: Riccardo Panicucci, Michael Monteith, Gang Li, Susan Arangio, Craig Berman, Michael Howland, Daniel Mulreany, Carl Dambkowski
  • Patent number: 12358878
    Abstract: An N-aromatic amide compounds with formula (I) is disclosed. The definitions of R1, R2, R3, R4, R5, R6, W1, W2 and W3 in the formula are the same as those in the description.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: July 15, 2025
    Assignee: Shenzhen EDK Pharmaceutical Technology Co., Ltd.
    Inventors: Guohong Yang, Lijun Yu, Junze He, Meijuan Duan
  • Patent number: 12351554
    Abstract: The present disclosure provides a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. Solvent screen, X-ray powder diffractogram, thermogravimetric mass spectroscopy, differential scanning calorimetry, 1H-NMR, dynamic vapor sorption, and UPLC data on each of the crystalline forms is presented, along with methods preparing each of the crystalline forms.
    Type: Grant
    Filed: June 13, 2024
    Date of Patent: July 8, 2025
    Assignee: Zylorion Health, Inc.
    Inventor: Peter Silverstone
  • Patent number: 12344617
    Abstract: Provided is a photochromic indolenaphthopyran compound having the skeletal structure of Formula (I): wherein R1 and R2 each independently have a steric bulk A, wherein at least one of R1 or R2 has a steric bulk A of at least 0.6, R3 and R4 each independently have a Hammett ?p value, and wherein the indolenaphthopyran compound has a calculated electronic steric factor of at least ?3.3.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 1, 2025
    Assignee: Transitions Optical, Ltd.
    Inventors: Ryan Stayshich, Darrin R. Dabideen, Zachary Smith, Robert W. Walters
  • Patent number: 12342823
    Abstract: The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound of the formula (II), which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarids and/or unwanted nematodes.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 1, 2025
    Assignee: Bayer Aktiengesellschaft
    Inventors: Stefan Herrmann, Reiner Fischer, Marita John
  • Patent number: 12344620
    Abstract: Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I).
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: July 1, 2025
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Chunli Shen, Yong Liu, Huanyu Bian, Chengde Wu, Jiahu Wu
  • Patent number: 12338230
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.
    Type: Grant
    Filed: January 22, 2024
    Date of Patent: June 24, 2025
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, William Greenlee
  • Patent number: 12297168
    Abstract: This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: May 13, 2025
    Assignee: ABIONYX PHARMA SA
    Inventor: Jean-Louis Henri Dasseux
  • Patent number: 12295962
    Abstract: The present invention provides co-crystal and salt forms, and compositions and methods thereof, useful for treating various diseases, disorders or conditions in which EP4 prostaglandin receptors are implicated in the mediation of a proliferative disorder, by the administration of small molecule therapeutics acting as inhibitors of prostaglandin EP4 receptor activity.
    Type: Grant
    Filed: April 2, 2024
    Date of Patent: May 13, 2025
    Assignee: AskAt Inc.
    Inventors: Alfredo C. Castro, David T. Jonaitis
  • Patent number: 12291499
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: May 6, 2025
    Assignee: Cybin IRL Limited
    Inventor: Alex Nivorozhkin
  • Patent number: 12291503
    Abstract: The present disclosure relates to the field of pharmaceutical technology, providing three crystalline forms, i.e., a crystalline form AB, a crystalline form M and a crystalline form F, of the compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminoformyl]cyclopropanecarbonyl]-amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoic acid for treatment of diseases related to protein kinases AXL and/or VEGFR2. The present disclosure also provides methods for preparing these three crystalline forms and pharmaceutical compositions comprising these three crystalline forms. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure all have good chemical stability, and the preparation processes of the three crystalline forms of the present disclosure are simple for implementation with high product yield and purity, allowing stable and mass production that facilitates promotion and application.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: May 6, 2025
    Assignee: Beijing Konruns Pharmaceutical Co., Ltd.
    Inventors: Xiaohua Sun, Long Wang, Hongzhen Yang, Huaizhong Hu
  • Patent number: 12286398
    Abstract: Provided herein are novel antibacterial compounds of Formula I. The compounds can be made through enzymatic oxidative dimerization in the presence of a suitable organism and one or more metal salts. Pathogenic bacteria exposed to the compound of Formula I do not develop resistance to these compounds even after prolonged exposure. Also provided herein are methods of treating bacterial infections, and method of killing or disinfecting bacteria.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 29, 2025
    Assignee: Yale University
    Inventors: Jason Crawford, Tyler Goddard, Hyun Bong Park, Jaymin Patel
  • Patent number: 12281102
    Abstract: The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 22, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Leslie A. Dakin, Timothy J. Senter, Jingrong Cao, Jon H. Come, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Francois Maltais, Suganthini S. Nanthakumar, Olivier Nicolas, Camil E. Sayegh, Tiansheng Wang, Stephanie Dorich, Lee Fader, Claudio Sturino, Janek Szychowski
  • Patent number: 12280028
    Abstract: The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: April 22, 2025
    Assignee: SEN-JAM PHARMACEUTICAL INC.
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl